CoChat

Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).

Ribas, Antoni, Hodi, F. Stephen, Kefford, Richard, Hamid, Omid, Daud, Adil, Wolchok, Jedd D., Hwu, Wen-Jen, Gangadhar, Tara C., Patnaik, Amita, Joshua, Anthony M., Hersey, Peter, Weber, Jeffrey S., Dronca, Roxana Stefania, Zarour, Hassane M., Gergich, Kevin, Li, Xiaoyun (Nicole), Iannone, Robert, Kang, Soonmo Peter, Ebbinghaus, Scot, Robert, Caroline · 2014 · Journal of Clinical Oncology
Cited by 147

The DOI matches its Crossref record.

Abstract

LBA9000^ Background: The humanized monoclonal IgG4 anti-PD-1 antibody MK-3475 has demonstrated durable antitumor activity in MEL and NSCLC. We evaluated MK-3475 efficacy and safety in a pooled analysis of 411 MEL pts. Methods: A nonrandomized cohort of ipilimumab-naive (IPI-N) and IPI-treated (IPI-T) pts treated with MK-3475 10 mg/kg Q2W, 10 mg/kg Q3W, or 2 mg/kg Q3W and randomized cohorts of IPI-N and IPI-T pts treated with 2 Q3W or 10 Q3W were included. Response was assessed every 12 wk by RECIST 1.1 by independent central review and by immune-related response criteria (irRC) by investigator. Results: 162 pts were treated at 2 Q3W, 192 at 10 Q3W, and 57 at 10 Q2W. 190 pts were IPI-N and 221 were IPI-T. As of the 10/18/2013 cutoff, all pts had ≥6 mo follow-up and >75% had ≥9 mo follow-up. Among the 365 pts with measurable disease at baseline, ORR by RECIST was 40% (95% CI 32%-48%) in IPI-N and 28% (95% CI 22%-35%) in IPI-T pts. Responses were durable (88% ongoing at analysis). Median PFS by RECIST was 24 wk in IPI-N and 23 wk in IPI-T pts. Median OS was not reached, with 1-y OS of 71% in all pts. Benefit was observed by both RECIST and irRC at all doses and schedules in IPI-N and IPI-T pts (Table). MK-3475 demonstrated activity in all major subgroups irrespective of ECOG PS, LDH levels, BRAFmutation, M stage, and number and type of prior therapy. Overall, 12% of pts experienced drug-related grade 3/4 AEs and 4% discontinued due to a drug-related AE. There were no drug-related deaths. Conclusions: MK-3475 showed durable responses and a manageable safety profile across dose and schedules in IPI-N and IPI-T MEL pts. The observed efficacy and safety suggest MK-3475 may be an appropriate treatment for all pts with MEL. Clinical trial information: NCT01295827. IPI-N IPI-T 2 Q3W n = 73 10 Q3W n = 76 10 Q2W n = 41 Total n = 190 2 Q3W n = 89 10 Q3W n = 116 10 Q2W n = 16 Total n = 221 RECIST ORR in pts with measurable disease, % 37 39 46 40 26 26 57 28 Median PFS, wk (95% CI) 36 (12-NR) 23 (12-36) 50 (14-NR) 24 (16-48) 22 (12-36) 17 (12-24) NR (12-NR) 23 (14-24) 24-wk PFS, % 52 46 57 51 45 40 67 44 irRC ORR, % 37 41 59 43 27 30 56 31 Median PFS, wk (95% CI) 36 (15-NR) 28 (13-NR) 84 (24-NR) 37 (24-84) 31 (22-48) 30 (24-NR) NR (12-NR) 36 (24-54) 24-wk PFS, % 57 52 61 56 57 56 73 58

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2014.32.15_suppl.lba9000

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 147

Metadata

Authors
Ribas, A., Hodi, F. S., Kefford, R., Hamid, O., Daud, A., Wolchok, J. D., Hwu, W.-J., Gangadhar, T. C., Patnaik, A., Joshua, A. M., Hersey, P., Weber, J. S., Dronca, R. S., Zarour, H. M., Gergich, K., Li, X. (., Iannone, R., Kang, S. P., Ebbinghaus, S., & Robert, C.
Venue
Journal of Clinical Oncology
Published
2014-05-20
Volume
32
Issue
15_suppl
Pages
LBA9000-LBA9000
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2211214375
Cited by
147
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL). https://app.cochat.ai/papers/10.1200/jco.2014.32.15_suppl.lba9000
The paper
Ribas, A., Hodi, F. S., Kefford, R., Hamid, O., Daud, A., Wolchok, J. D., Hwu, W.-J., Gangadhar, T. C., Patnaik, A., Joshua, A. M., Hersey, P., Weber, J. S., Dronca, R. S., Zarour, H. M., Gergich, K., Li, X. (., Iannone, R., Kang, S. P., Ebbinghaus, S., & Robert, C. (2014). Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL). Journal of Clinical Oncology. https://doi.org/10.1200/jco.2014.32.15_suppl.lba9000

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.